Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

9

Possibly Marketed Outside US

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Fatty acid desaturase 1

2

Fatty acid desaturase 2

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

11

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1921

9

1994

2

2008

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

penetration of radioactive iodine into the thyroid gland

9

Parenteral Nutrition

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Preventing

9

Curative

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Rollett, A.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

12

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

12

FDA UNII

12

PUBCHEM

11

EPA CompTox

10

WIKIPEDIA

9

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

DERMATOLOGICALS

1

RESPIRATORY SYSTEM

1

SENSORY ORGANS

1

VARIOUS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ALL OTHER THERAPEUTIC PRODUCTS

1

ANTISEPTICS AND DISINFECTANTS

1

COUGH AND COLD PREPARATIONS

1

OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ALL OTHER THERAPEUTIC PRODUCTS

1

ANTISEPTICS AND DISINFECTANTS

1

EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS

1

OTHER OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antidotes

1

Expectorants

1

Other ophthalmologicals

1

Silver compounds

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

9

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 12 results

First page disabled
Previous page disabled
1
Next page
Next page

IODIDE ION

09G4I6V86Q

Export Data
Search for Structure

Status:

US Approved Rx (2002)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

SILVER

3M4G523W1G

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2008

Class (Stereo):

CHEMICAL (ACHIRAL)

Silver is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. According to FDA final rule, all over-the-counter drug products containing colloidal silver ingredients or silver salts for internal or external use...

are not generally recognized as safe and effective and are misbranded.

SODIUM LINOLENATE

I5OYY436YI

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 1994

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Fatty acid desaturase 2

Fatty acid desaturase 1

Conditions:

Parenteral Nutrition

Alpha-linolenic acid (ALA), an 18-carbon omega-3 essential fatty acid, is the precursor of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). ALA cannot be synthesized by humans and therefore must be entirely acquired from exogenous sources....

Evidence for the essentiality of ALA was first provided by a study showing that ALA supplementation reversed the abnormal neurologic signs observed in a 6-year-old girl who suffered from sensory loss and visual complications. Most of the ALA is catabolized via beta-oxidation for energy generation, and a small proportion of it undergoes conversion to produce another two potent members of omega-3 PUFA family: EPA and DHA. Delta 6 desaturase (D6D) enzyme is responsible the conversion of ALA to DHA. Although not conclusive, it was suggested, that the benefits associated with ALA seem to stem mainly from EPA and DHA, and as major consequence of ALA deficiency it appears that EPA and DHA are not adequately produced.

POTASSIUM OXIDE

58D606078H

Export Data
Search for Structure

Status:

US Approved Rx (2002)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

Iodine, atomic

5D3DB66WM3

Export Data
Search for Structure

Status:

US Approved Rx (2002)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

POTASSIUM FLUORIDE TETRAHYDRATE

1V272UD7M7

Export Data
Search for Structure

Status:

US Approved Rx (2002)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

ETHYLENEDIAMINE DIHYDRIODIDE

721M52NQ5L

Export Data
Search for Structure

Status:

US Approved Rx (2002)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

POTASSIUM BISULFIDE

SX1L03AL9I

Export Data
Search for Structure

Status:

US Approved Rx (2002)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

Potassium iodide

1C4QK22F9J

Export Data
Search for Structure

Status:

US Approved Rx (2002)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

Sodium iodide

F5WR8N145C

Export Data
Search for Structure

Status:

US Approved Rx (2002)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

Showing 1 - 10 of 12 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1